Please assess the completion status of the following clinical trial:

Trial Title: Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who signed an Informed Consent Form prior to initiation of any study-related procedure~* Patients with moderate to severe stable COPD (clinical diagnosis in compliance with GOLD 2008)~* Current or ex-smokers with a smoking history ≥ 10 pack years. (Ten pack-years were defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.).~* Patients with a post-bronchodilator FEV1 ≥ 40 and \< 70% of the predicted normal, and postbronchodilator FEV1/FVC \< 0.7 during screening. (Post referred to the highest post-bronchodilator value after inhalation of 80 μg ipratropium bromide)~* Increase in FEV1 from pre- to post-bronchodilator assessment of ≥ 5%~Exclusion Criteria:~* Pregnant women or nursing mothers~* Women of child-bearing potential~* Patients who had a COPD exacerbation (whether hospitalized or not) in the 6 weeks prior to Visit 1 or between Visit 1 and Visit 4~* Patients who had a lower respiratory tract infection in the 6 weeks prior to Visit 1~* Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia~* Patients with resting (5 min) oxygen SaO2 (or SpO2) saturation on room air of \< 85%~* Patients with a maximum workload (Wmax) value \< 20 W (as determined by the incremental cycle endurance test) at Visit 2.~* Patients whose exercise endurance time at sub-maximal workload was above 25 min at baseline~* Patients with a clinically significant abnormality on the screening or baseline ECG who in the judgment of the investigator would have been at potential risk if enrolled into the study~* Patients with a history of long QT syndrome or whose QTc was prolonged (\> 450 ms for males and \> 470 ms females) at screening (Fredericia's correction)~Other protocol-defined inclusion/exclusion criteria applied

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 followed by Placebo (Type: EXPERIMENTAL): Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days~Period 2: Matching placebo via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study.
- Placebo followed by NVA237 (Type: EXPERIMENTAL): Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).